prothymosin alpha is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
Heritable connective tissue diseases are rare, each disorder estimated at one to ten per 100,000, of which Marfan syndrome is the most common. It is carried by the FBN1 gene on chromosome 15, which encodes the connective protein fibrillin-1, inherited as a dominant trait. This protein is essential for synthesis and maintenance of elastic fibers. Since these fibers are particularly abundant in the aorta, ligaments, and the ciliary zonules of the eye, these areas are among the worst affected. Everyone has a pair of FBN1 genes and, because transmission is dominant, those who have inherited one affected FBN1 gene from either parent will have Marfan syndrome. Although it is most frequently inherited as an autosomal dominant, there is no family history in 25% of cases. Recruiting practices aimed at attracting athletes who are unusually tall or who have an unusually wide arm span (characteristics of Marfan syndrome) can increase the prevalence of the syndrome within sports such as basketball and volleyball.
The stolon is ready to harvest two to three months after planting. It must be harvested before flowering. Harvesting the stolon is done by manual labor. For this step, the field is not drained. The stolon is pulled out of the water by pulling and shaking the young leaves in the shallow water. The first leaves and flowers can be harvested three months after planting. Flowers can be picked every two days during summer and every three days during the colder season. Four months after planting, the production of flowers has its climax. The harvest of flowers is usually done by hand for three to four months. Seeds and seed pods can be harvested when they turn black four to eight months after planting. After sun drying for two to three days, they are processed by mechanical tools to separate seed coats and embryos. The rhizomes mature to a suitable stage for eating in approximately six to nine months. Early varieties are harvested in July until September and late varieties from October until March, after the ponds or fields are drained. The large, starch-rich rhizomes are easy to dig out of the drained soil. In small-scale production, they are harvested by hand using fork-like tools. In Japan and on bigger farms, manual labour harvesting is fully replaced by machines.
Yuchanyan is an early Neolithic cave site in Dao County (Daoxian), Hunan, China. The site yielded sherds of ceramic vessels and other artifacts which were dated by analysis of charcoal and bone collagen, giving a date range of 17,500 to 18,300 years old for the pottery. The pottery specimens may be the oldest known examples of pottery. The cave yielded fragmentary remains of 2 or more ceramic vessels, in addition to large amounts of ash, a rich animal bone assemblage, cobble and flake artifacts, bone tools, and shell tools. The artifacts indicate that the cave was a Late Paleolithic foragers' camp. Here we report on the radiocarbon ages of the sediments based on analyses of charcoal and bone collagen. The best-preserved charcoal and bone samples were identified by prescreening in the field and laboratory. The dates range from around 21,000 to 13,800 cal BP. The age of the ancient pottery ranges between 18,300 and 15,430 cal BP. Charcoal and bone collagen samples located above and below one of the fragments produced dates of around 18,000. These ceramic potsherds therefore provide some of the earliest evidence for pottery making in China.
Ion mobility spectrometry-mass spectrometry (IMS/MS or IMMS) is a technique where ions are first separated by drift time through some neutral gas under an applied electrical potential gradient before being introduced into a mass spectrometer. Drift time is a measure of the collisional cross section relative to the charge of the ion. The duty cycle of IMS (the time over which the experiment takes place) is longer than most mass spectrometric techniques, such that the mass spectrometer can sample along the course of the IMS separation. This produces data about the IMS separation and the mass-to-charge ratio of the ions in a manner similar to LC-MS. The duty cycle of IMS is short relative to liquid chromatography or gas chromatography separations and can thus be coupled to such techniques, producing triple modalities such as LC/IMS/MS.
Sources: en.wikipedia.org
=== Generic names === Benorterone is the generic name of the drug and its INNTooltip International Nonproprietary Name and USANTooltip United States Adopted Name. It is also known by its developmental code names SKF-7690 and FC-612.
=== China and North Korea === In 2019, Galloway defended the authorities' crackdown on protests in Hong Kong. He told China Global Television Network: "These people should know that Hong Kong is China. No country, absolutely no country, will allow an existential threat to emerge on its territory". In 2022, he said there were no internment camps for Uighurs in China. He stated that China had established "re-education centres" to steer terrorists away from the path of extremism. Galloway said, after spending time in North Korea, he "does not agree with the North Korean system" and would not like to live there. He said "there have been achievements in North Korea ... They have a cohesive, pristine actually, innocent culture, a culture not penetrated by globalisation and Western mores". During a period of tension between North and South Korea in 2013, Galloway said "North Korea has no intention to harm any of us. North Korea's problem is with South Korea. ... South Korea exists because America invaded Korea, killed millions of people, divided the country and continues to garrison South Korea with military bases, nuclear weapons, chemical and biological weapon". He blamed the United States for "war mongering" during the crisis and called South Korea its "puppet state".
== Life cycle == The life cycle of C. chanhua in southern China as observed and described by Zha, Ling-Sheng et al. in 2019 follows. During mid-late summer, conidia of C. chanhua attach to the surface of a cicada nymph's body within the soil which germinate and form germ tubes that can penetrate below the surface and form hyphae. After two to three days of absorbing the cicada's nutrients and reproducing, they can occupy the entire body. Hyphae turn to mycelia which cause the nymph to die from absorbing water and nutrients and producing mycotoxins. After the nymph is killed, the fungus forms a sclerotium and produce antibiotics to keep the body from rotting. When temperatures rise again, either that year or the following, mycelia are produced once more to form synnemata that eventually break through the soil to grow above ground. The synnema branches to form multiple conidiophores and chained conidia. The conidia are dispersed by air or water, leading them back to the soil, where they use water flow to infiltrate the soil until they make contact with another nymph and infect.
==== European Union ==== In June 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of the combination for the treatment of cystic fibrosis. It was approved for medical use in the European Union in August 2020.
Appearing to meet the concern, in Überseering BV v Nordic Construction GmbH the Court of Justice held that a German court could not deny a Dutch building company the right to enforce a contract in Germany, simply because it was not validly incorporated in Germany. Restrictions on freedom of establishment could be justified by creditor protection, labour rights to participate in work, or the public interest in collecting taxes. But in this case denial of capacity went too far: it was an "outright negation" of the right of establishment. Setting a further limit, in Cartesio Oktató és Szolgáltató bt the Court of Justice held that because corporations are created by law, they must be subject to any rules for formation that a state of incorporation wishes to impose. This meant the Hungarian authorities could prevent a company from shifting its central administration to Italy, while it still operated and was incorporated in Hungary. Thus, the court draws a distinction between the right of establishment for foreign companies (where restrictions must be justified), and the right of the state to determine conditions for companies incorporated in its territory, although it is not entirely clear why.
Sources: en.wikipedia.org
== External links == Anatomy photo: Digestive/mammal/system1/system10 - Comparative Organology at University of California, Davis - "Mammal, whole system (LM, Low)" Histology image: 55_07 at the University of Oklahoma Health Sciences Center (vermiform appendix)
Fresh frozen plasma is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. It is of critical importance in the treatment of many types of trauma which result in blood loss, and is therefore kept stocked universally in all medical facilities capable of treating trauma (e.g., trauma centers, hospitals, and ambulances) or that pose a risk of patient blood loss such as surgical suite facilities.
Steiner (1945), scholar of social policy and fourth president of the Brookings Institution Richard Heffner (1946), professor and host of The Open Mind Fritz Stern (1946), Seth Low Professor of History Emeritus; pre-eminent in German studies George Herbert Borts (1947), economist at Brown University and managing editor of The American Economic Review 1969–1980 William Bell Dinsmoor Jr. (1947), Classical archaeologist and architectural historian John Michael Montias (1947), economist and art historian at Yale University Harold E. Pagliaro (1947), professor of English literature at Swarthmore College Howard Stein (1947), philosopher at the University of Chicago Lambros Comitas (1948), anthropologist Elihu Katz (1948), sociologist and communication scholar, known for developing the two-step flow of communication theory Norman Kelvin (1948), literary scholar, professor at City College of New York and Graduate Center, CUNY Victorino Tejera (1948), professor of philosophy and comparative literature at Stony Brook University Uriel Weinreich (1948), linguist and professor at Columbia University Albert Elsen (1949), professor at Stanford University and Auguste Rodin expert Donald M. Friedman (1949), professor of Renaissance literature at University of California, Berkeley Marvin Harris (1949), anthropologist famous for developing cultural materialism Anthony Leeds (1949), anthropologist, professor at Boston University Robert F.
The Gold Book, formally titled Compendium of Chemical Terminology, contains internationally accepted definitions for terms in chemistry. Work on the first edition was initiated by Victor Gold, thus spawning its informal name. The first edition was published in 1987 (ISBN 0-63201-765-1). The second (ISBN 0-86542-684-8), edited by A. D. McNaught and A. Wilkinson, was published in 1997. A slightly expanded version is also freely searchable online. Translations have also been published in French, Spanish and Polish.
Using molecular oxygen alkanes can be oxidized to form alcohols, secondary alcohols to ketones, acetals to esters and alkenes to epoxides. Amides can be converted into carbonyl compounds with N-hydroxyphthalimide and cobalt(II)salts under mild conditions.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.